Markets Gone Wild

FDA Reaffirms Priority Review for Insmed’s NDA for Brensocatib, No Advisory Committee Meeting Scheduled Insmed Incorporated, a leading biopharmaceutical company, recently announced that the US Food and Drug Administration (FDA) has reaffirmed the application for their New Drug Application (NDA) for brensocatib as being under priority review. This means that the FDA is giving priority…

Understanding Your Legal Options After Suffering Losses in XPLR Infrastructure, LP (XIFR) If you have invested in XPLR Infrastructure, LP (XIFR) and have experienced financial losses, you may be wondering about your potential options for recovery under federal securities laws. In this article, we will provide you with essential information on this topic. What is…

Exciting Rock Samples Discovered at ZEUS North America’s Cuddy Mountain Project Vancouver, BC – March 17, 2025 – ZEUS North America Mining Corp. (ZEUS), a leading mining company with a strong presence in the CSE, OTCQB, and Frankfurt Stock Exchanges, is thrilled to share the results of its recent exploration program at the Cuddy Mountain…

Class Action Lawsuit Filed Against Marqeta, Inc. Bronstein, Gewirtz & Grossman, LLC Notifies Investors January 31, 2025 In a recent development, Bronstein, Gewirtz & Grossman, LLC, a prominent law firm, has announced that a class action lawsuit has been filed against Marqeta, Inc. (“Marqeta” or “the Company”) (NASDAQ:MQ) and certain of its officers. The lawsuit…

Genomma Lab International Announces Cash Dividend of $200 Million Mexico City, Mexico, March 6, 2025 – Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (“Genomma Lab” or “the Company”), a leading pharmaceutical and personal care product company in Mexico with an expanding international presence, made an important announcement today. The Company filed a Notice of…

Blog Post Article: Downgrading PG Stock Rating to HOLD A Closer Look at the Recent Developments After careful consideration, I have made the decision to downgrade my rating on PG stock to HOLD from my previous BUY rating. Several new catalysts have emerged since my last assessment, leading me to believe that there is no…